Roche: FDA approves drug combo Venclexta plus Gazyva for previously untreated chronic lymphocytic leukemia




  • In Business
  • 2019-05-16 05:43:19Z
  • By Reuters
Swiss drugmaker Roche
Swiss drugmaker Roche's logo is seen at their headquarters in Basel  

ZURICH (Reuters) - Roche said on Thursday that the U.S. Food and Drug Administration had approved a treatment using its drugs Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukemia.

"Venclexta plus Gazyva is the only chemotherapy-free option of fixed duration that provides durable responses to help people live longer without progression of their disease, compared to a standard-of-care," Roche's Chief Medical Officer Sandra Horning said in a statement.

(Reporting by Brenna Hughes Neghaiwi; Editing by Michelle Martin)

COMMENTS

More Related News

Coronavirus (COVID-19) Update: Daily Roundup
Coronavirus (COVID-19) Update: Daily Roundup

Coronavirus (COVID-19) Update: Daily RoundupPR NewswireSILVER SPRING, Md., May 29, 2020SILVER SPRING, Md.

U.S. FDA approves Eli Lilly
U.S. FDA approves Eli Lilly's diagnostic agent for Alzheimer's disease
  • US
  • 2020-05-28 22:16:09Z

Abnormal versions of two proteins, amyloid and tau, are involved in Alzheimer's disease and considered hallmarks of the brain-wasting disease. The FDA said Lilly's compound, Tauvid, is the first drug that has gained the approval to detect tau tangles within the brain.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business